Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
2315.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.06B
Close$
$203.31
193.8% upside
Current Fair Value
193.8% upsideUndervalued by 193.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.06 Billion |
|---|---|
| Enterprise Value | $28.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.43 |
| Beta | 0.14 |
| Outstanding Shares | 443,498,000 |
Return
| Return on Equity | 20.59% |
|---|---|
| Return on Assets | 13.69% |
| Return on Invested Capital | 21.38% |
Valuation & Multiples
| P/E Ratio | 69.31 |
|---|---|
| PEG | 17.23 |
| Price to Sales | 11.53 |
| Price to Book Ratio | 13.84 |
| Enterprise Value to Revenue | 9.73 |
| Enterprise Value to EBIT | 41.85 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.41 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
1,443 employees
CEO: Yuelei Shen Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based ...